L Brancaccio

478 total citations
17 papers, 388 citations indexed

About

L Brancaccio is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, L Brancaccio has authored 17 papers receiving a total of 388 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in L Brancaccio's work include Lung Cancer Research Studies (11 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer therapeutics and mechanisms (6 papers). L Brancaccio is often cited by papers focused on Lung Cancer Research Studies (11 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer therapeutics and mechanisms (6 papers). L Brancaccio collaborates with scholars based in Italy and United States. L Brancaccio's co-authors include Cesare Gridelli, Ciro Gallo, Francesco Perrone, Massimo Di Maïo, L. Isa, Santi Barbera, Giovanni Pietro Ianniello, Emiddio Barletta, Paolo Maione and Giovanni Palazzolo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

L Brancaccio

17 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L Brancaccio Italy 9 271 226 63 55 43 17 388
Francesco Carrozza Italy 10 183 0.7× 230 1.0× 63 1.0× 58 1.1× 45 1.0× 26 384
C. Roemer-Bécuwe France 8 152 0.6× 63 0.3× 33 0.5× 105 1.9× 15 0.3× 15 346
Yoshitaka Ogata Japan 11 174 0.6× 132 0.6× 10 0.2× 40 0.7× 23 0.5× 26 272
Sanne ten Hoorn Netherlands 9 226 0.8× 96 0.4× 17 0.3× 62 1.1× 30 0.7× 16 458
Fumihiko Hojo Japan 12 199 0.7× 188 0.8× 11 0.2× 79 1.4× 28 0.7× 20 414
Suzanna Bota France 10 170 0.6× 192 0.8× 10 0.2× 18 0.3× 8 0.2× 21 318
Jesús García Mata Spain 10 170 0.6× 91 0.4× 7 0.1× 37 0.7× 12 0.3× 26 286
Edit Remák United Kingdom 10 94 0.3× 132 0.6× 6 0.1× 61 1.1× 12 0.3× 31 336
Jaime Sanz‐Ortiz Spain 8 75 0.3× 34 0.2× 19 0.3× 68 1.2× 132 3.1× 17 313
Christopher V. Lutman United States 7 53 0.2× 33 0.1× 35 0.6× 58 1.1× 14 0.3× 9 409

Countries citing papers authored by L Brancaccio

Since Specialization
Citations

This map shows the geographic impact of L Brancaccio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Brancaccio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Brancaccio more than expected).

Fields of papers citing papers by L Brancaccio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Brancaccio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Brancaccio. The network helps show where L Brancaccio may publish in the future.

Co-authorship network of co-authors of L Brancaccio

This figure shows the co-authorship network connecting the top 25 collaborators of L Brancaccio. A scholar is included among the top collaborators of L Brancaccio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Brancaccio. L Brancaccio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Palmieri, Emiliano A., et al.. (2012). Lytic failure in the current pharmacointensive ST-elevated acute myocardial infarction care. Journal of Cardiovascular Medicine. 14(1). 35–42. 1 indexed citations
2.
Martucci, Paola, Piersante Sestini, Pier Aldo Canessa, et al.. (2009). Smoking cessation in patients requiring bronchoscopy: The Bronchoscopy AntiSmoking Study (BASIS). Respiratory Medicine. 104(1). 61–66. 3 indexed citations
3.
Gridelli, Cesare, Ermelinda De Maio, Santi Barbera, et al.. (2008). The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients. Lung Cancer. 61(1). 67–72. 8 indexed citations
4.
Gridelli, Cesare, Ciro Gallo, Massimo Di Maïo, et al.. (2004). A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. British Journal of Cancer. 91(12). 1996–2004. 143 indexed citations
5.
Maïo, Massimo Di, Cesare Gridelli, Ciro Gallo, et al.. (2004). Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. British Journal of Cancer. 90(12). 2288–2296. 102 indexed citations
6.
Marinis, Filippo de, Fabrizio Nelli, Maria Rita Migliorino, et al.. (2003). Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy‐proven Stage IIIA(N2) nonsmall cell lung carcinoma. Cancer. 98(8). 1707–1715. 33 indexed citations
7.
Gridelli, Cesare, Antônio Rossi, Emiddio Barletta, et al.. (2002). Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study. Lung Cancer. 36(3). 327–332. 14 indexed citations
8.
Gridelli, Cesare, L Brancaccio, Modesto DʼAprile, et al.. (2002). Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study.. PubMed. 21(6A). 4179–83. 4 indexed citations
9.
Gridelli, Cesare, S. Cigolari, Giovanni Pietro Ianniello, et al.. (2000). Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study. Lung Cancer. 28(3). 237–244. 6 indexed citations
10.
Gridelli, Cesare, Francesco Perrone, Giovanni Pietro Ianniello, et al.. (1998). Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole.. Journal of Clinical Oncology. 16(4). 1414–1419. 22 indexed citations
11.
12.
Gridelli, Cesare, Giovanni Pietro Ianniello, L Brancaccio, et al.. (1997). 212 Carboplatin plus vinorelbine: A new active regimen in extensive small cell lung cancer. Results of a multicenter phase II study. Lung Cancer. 18. 55–55. 5 indexed citations
13.
Gridelli, Cesare, L Brancaccio, Franco Perrone, et al.. (1997). Carboplatin plus vinorelbine: A new active regimen in extensive small cell lung cancer. Results of a multicenter phase II study. European Journal of Cancer. 33. S231–S231. 3 indexed citations
14.
Ianniello, Giovanni Pietro, Giuseppe De Cataldis, Pasquale Comella, et al.. (1996). Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: A multicenter randomized clinical trial. Cancer. 78(1). 63–69. 1 indexed citations
15.
Ianniello, Giovanni Pietro, Giuseppe De Cataldis, Pasquale Comella, et al.. (1996). Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: A multicenter randomized clinical trial. Cancer. 78(1). 63–69. 13 indexed citations
16.
Gridelli, Cesare, Modesto DʼAprile, Carlo Curcio, et al.. (1994). Carboplatin plus epirubicin plus VP-16, concurrent ‘split course’ radiotherapy and adjuvant surgery for limited small cell lung cancer. Lung Cancer. 11(1-2). 83–91. 7 indexed citations
17.
Ianniello, Giovanni Pietro, et al.. (1994). Enhancement of C.E.V combination (cisplatin, epirubicin, vindesine) in advanced NSCLC by lonidamine. A phase II randomized trial. Lung Cancer. 11. 130–130. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesco Carrozza Breakdown of academic impact, for papers by C. Roemer-Bécuwe Breakdown of academic impact, for papers by Yoshitaka Ogata Breakdown of academic impact, for papers by Sanne ten Hoorn Breakdown of academic impact, for papers by Fumihiko Hojo Breakdown of academic impact, for papers by Suzanna Bota Breakdown of academic impact, for papers by Jesús García Mata Breakdown of academic impact, for papers by Edit Remák Breakdown of academic impact, for papers by Jaime Sanz‐Ortiz Breakdown of academic impact, for papers by Christopher V. Lutman
Rankless by CCL
2026